This is the text extract for April Tender Notification, browse documents here.

---

30 April 2010

TENDER RESULTS

The PHARMAC Board (or Chief Executive under delegated authority) has resolved to accept tenders for Sole Subsidised Supply and Hospital Supply Status for some of the products included in the Invitation to Tender dated 21 December 2007, the Invitation to Tender dated 23 December 2008 and the Invitation to Tender dated 4 December 2009. Some of the pharmaceuticals that will be delisted when the period of sole supply commences may be subject to existing listing contracts with PHARMAC. Suppliers of pharmaceuticals that are subject to such contracts should continue to supply their pharmaceuticals under those contracts until such time as the pharmaceuticals are delisted and PHARMAC will continue to subsidise their pharmaceuticals accordingly. Product Notification Forms Please note that for all changes (price change, pack size change, new listing etc) to be effective in the Pharmaceutical Schedule (including Section H) from 1 June 2010, suppliers are required to notify PHARMAC and the Guild by 4pm 12th May 2010. More information and product notification forms can be downloaded from our website – www.pharmac.govt.nz/schedule.asp. 2007/08 Tender Community pharmaceutical tenders – Section B of the Pharmaceutical Schedule 1. Tenders awarded to an unlisted pharmaceutical – listing for tender winning brand at the tender subsidy will occur on 1 June 2010 and Sole Subsidised Supply commences on 1 September 2010.

The decision was as follows:

Chemical Name Tramadol hydrochloride

Presentation; Pack size and type Cap 50 mg; 100 capsules, blister

New tender subsidy $6.95

Sole supply brand (Supplier) Arrow-Tramadol (Arrow)

Hospital pharmaceutical tenders – Section H of the Pharmaceutical Schedule 2. Tender awarded to a listed pharmaceutical where an alternative brand is already listed – listing of the hospital tender winning brand of the pharmaceutical will occur in Part II of Section H of the Pharmaceutical Schedule on 1 June 2010; DV Limits and DV pharmaceuticals will apply from 1 August 2010; delisting of the other brand in Section H will occur on 1 August 2010.

The decision was as follows:

Chemical Name

Presentation; Pack size and type

Hospital Supply Brand (Supplier)

Pack Price

DV Limit

DV Pharmaceuticals Brand Name (Supplier) AFT (AFT) Tramal (CSL Biotherapies) Tramedo (Mylan)

Tramadol hydrochloride

Cap 50 mg; 100 capsules, blister

Arrow-Tramadol (Arrow)

$6.95

1%

Products where no tender is to be awarded for Sole Subsidised Supply or Hospital Supply Status The PHARMAC Board (or Chief Executive under delegated authority) resolved not to award tenders for Sole Subsidised Supply or Hospital Supply Status for some of the products listed in the Invitation to Tender, dated 21 December 2007.

A345531 - qA15909

---

The decisions were as follows:

Chemical Name Tramadol hydrochloride Tramadol hydrochloride Tramadol hydrochloride Tramadol hydrochloride Tramadol hydrochloride Tramadol hydrochloride Tramadol hydrochloride Tramadol hydrochloride

Line Item Inj 50 mg per ml, 1 ml Inj 50 mg per ml, 2 ml Oral liq 100 mg per ml Tab sustained release 50 mg Tab sustained release 100 mg Tab sustained release 150 mg Tab sustained release 200 mg Tab sustained release 300 mg

2008/09 Tender Community pharmaceutical tenders – Section B of the Pharmaceutical Schedule 3. Tenders awarded to pharmaceuticals where at least one other brand is listed – listing for the tender winning brand at the tender subsidy will occur on 1 June 2010, reference pricing of nontender winning brand will occur on 1 August 2010 and Sole Subsidised Supply will commence on 1 November 2010.

The decisions were as follows:

Chemical Name

Presentation; Pack size and type Tab 5 mg; 90 tablets, bottle Tab 10 mg; 90 tablets, bottle

Current subsidy $2.19 $2.76

New tender subsidy $1.98 $2.44

Sole supply brand (Supplier) Arrow-Enalapril 5 (Arrow) Arrow-Enalapril 10 (Arrow) Arrow-Enalapril 20 (Arrow)

Brands affected by reference pricing and delisting m-Enalapril (Multichem) m-Enalapril (Multichem) m-Enalapril (Multichem)

Enalapril Enalapril

Enalapril

Tab 20 mg; 90 tablets, bottle

$3.68

$3.24

Hospital pharmaceutical tenders – Section H of the Pharmaceutical Schedule 4. Tenders awarded to listed pharmaceuticals where an alternative brand is already listed – listing for hospital tender winning brands of the pharmaceutical will occur in Section H of the Pharmaceutical Schedule on 1 June 2010; DV Limits and DV pharmaceuticals will apply from 1 August 2010; de-listing of other brands in Section H will occur on 1 August 2010.

The decisions were as follows:

Chemical Name

Presentation; Pack size and type

Hospital Supply Brand (Supplier) Arrow-Enalapril 5 (Arrow) Arrow-Enalapril 10 (Arrow) Arrow-Enalapril 20 (Arrow)

Pack Price

DV Limit

DV Pharmaceuticals Brand Name (Supplier) m-Enalapril (Multichem) Redopril (Novartis) Renitec (MSD) m-Enalapril (Multichem) Redopril (Novartis) Renitec (MSD) m-Enalapril (Multichem) Redopril (Novartis) Renitec (MSD) Camptosar (Pfizer) DBL Irinotecan (Hospira) Irinotecan Actavis 40 (CSL Biotherapies) Mylan (Mylan)

Enalapril

Tab 5 mg; 90 tablets, bottle

$1.98

1%

Enalapril

Tab 10 mg; 90 tablets, bottle

$2.44

1%

Enalapril

Tab 20 mg; 90 tablets, bottle

$3.24

1%

Irinotecan*

Inj 20 mg per ml, 2 ml; 1 injection, vial

Irinotecan-Rex (Rex Medical)

$41.00

1%

A345531 - qA15909

Page 2 of 5

---

Chemical Name

Presentation; Pack size and type

Hospital Supply Brand (Supplier)

Pack Price

DV Limit

DV Pharmaceuticals Brand Name (Supplier) Camptosar (Pfizer) DBL Irinotecan (Hospira) Irinotecan Actavis 40 (CSL Biotherapies) Mylan (Mylan)

Irinotecan*

Inj 20 mg per ml, 5 ml; 1 injection, vial

Irinotecan-Rex (Rex Medical)

$100.00

1%

* Irinotecan-Rex will also be listed in Section B of the Pharmaceutical Schedule for PCT only from 1 June 2010. The subsidy of irinotecan inj 1 mg for ECP will reduce from $3.19 per 1 mg to $1.04 per 1 mg from 1 August 2010 in Section B of the Pharmaceutical Schedule.

2009/10 Tender Community pharmaceutical tenders – Section B of the Pharmaceutical Schedule 5. Tenders awarded to listed pharmaceuticals where no other brand is listed – subsidy changes (where applicable) on 1 June 2010 and Sole Supply Status commences 1 August 2010.

The decisions were as follows:

Chemical Name Dexamethasone sodium phosphate Dexamethasone sodium phosphate

Presentation; Pack size and type Inj 4 mg per ml, 1 ml; 5 injections, vials Inj 4 mg per ml, 2 ml; 5 injections, ampoules

Current Subsidy $21.50 $31.00

New tender subsidy $21.50 $31.00

Sole supply brand (Supplier) Hospira (Hospira) Hospira (Hospira)

6. Tenders awarded to listed pharmaceuticals where no other brand is listed – subsidy changes (where applicable) on 1 July 2010 and Sole Supply Status commences 1 October 2010.

The decisions were as follows:

Chemical Name Bisacodyl Colchicine Cyclophosphamide Dexamethasone Paraffin liquid with soft white paraffin

Presentation; Pack size and type Tab 5 mg; 200 tablets, bottle Tab 500 µg; 100 tablets, bottle Tab 50 mg; 50 tablets, bottle Eye drops 0.1 %; 5 ml OP, bottle Eye oint with soft white paraffin; 3.5 g OP, bottle

Current Subsidy $5.09 $9.60 $25.71 $4.50 $3.63 $1.68 $1.82 $213.19 $2.25

New tender subsidy $4.99 $9.60 $25.71 $4.50 $3.63 $1.68 $1.78 $213.19 $1.99

Sole supply brand (Supplier) Lax-Tab (AFT) Colgout (Aspen) Cycloblastin (Pfizer) Maxidex (Alcon) Lacri-Lube (Allergan) AFT (AFT) AFT (AFT) Mycobutin (Pfizer) Salapin (AFT)

Phenoxymethylpenicillin Grans for oral liq 125 mg per 5 ml; 100 ml, (Penicillin V) bottle Phenoxymethylpenicillin Grans for oral liq 250 mg per 5 ml; 100 ml, (Penicillin V) bottle Rifabutin Salbutamol Cap 150 mg; 30 capsules, blister Oral liq 2 mg per 5 ml; 150 ml, bottle

Hospital pharmaceutical tenders – Section H of the Pharmaceutical Schedule 7. Tenders awarded to listed pharmaceuticals where only the current brand is listed – price changes (where applicable) for hospital tender winning brands of the pharmaceuticals will occur in Section H of the Pharmaceutical Schedule on 1 June 2010; DV Limits and DV Pharmaceuticals will apply from 1 August 2010

The decisions were as follows:

Chemical Name Dexamethasone sodium phosphate

Presentation; Pack size and type Inj 4 mg per ml, 1 ml; 5 injections, vials

Hospital Supply Brand (Supplier) Hospira (Hospira)

Pack Price $21.50

DV Limit 1%

DV Pharmaceuticals Brand Name (Supplier) (B)

A345531 - qA15909

Page 3 of 5

---

Chemical Name Dexamethasone sodium phosphate Vincristine sulphate^ Vincristine sulphate^

Presentation; Pack size and type Inj 4 mg per ml, 2 ml; 5 injections, ampoules Inj 1 mg per ml, 1 ml; 5 inejctions, vials Inj 1 mg per ml, 2 ml, 5 injections, vials

Hospital Supply Brand (Supplier) Hospira (Hospira) Hospira (Hospira) Hospira (Hospira)

Pack Price $31.00 $108.00 $116.00

DV Limit 1% 1% 1%

DV Pharmaceuticals Brand Name (Supplier) (B) (B) (B)

^The subsidy of vincristine sulphate inj 1 mg for ECP will reduce from $21.46 per 1 mg to $15.77 per 1 mg from 1 June 2010 in Section B

of the Pharmaceutical Schedule. The prices for Hospira’s vincristine sulphate injections will decrease in Section B of the Pharmaceutical Schedule from 1 June 2010 also.

8. Tenders awarded to listed pharmaceuticals where only the current brand is listed – price changes (where applicable) for hospital tender winning brands of the pharmaceuticals will occur in Section H of the Pharmaceutical Schedule on 1 July 2010; DV Limits and DV Pharmaceuticals will apply from 1 September 2010

The decisions were as follows:

Chemical Name

Presentation; Pack size and type

Hospital Supply Brand (Supplier)

Pack Price

DV Limit

DV Pharmaceuticals Brand Name (Supplier) Apo-Bisacodyl (Apotex) Dulcolax (Boehringer Ingelheim) (B) Endoxan (Baxter) (B) (B) (B) (B) Ventolin (GSK)

Bisacodyl Colchicine Cyclophosphamide Dexamethasone Phenoxymethylpenicillin (Penicillin V) Phenoxymethylpenicillin (Penicillin V) Rifabutin Salbutamol

Tab 5 mg; 200 tablets, bottle Tab 500 µg; 100 tablets, bottle Tab 50 mg; 50 tablets, bottle Eye drops 0.1 %; 5 ml, bottle Grans for oral liq 125 mg per 5 ml; 100 ml, bottle Grans for oral liq 250 mg per 5 ml; 100 ml, bottle Cap 150 mg; 30 capsules, blister Oral liq 2 mg per 5 ml; 150 ml, bottle

Lax-Tab (AFT) Colgout (Aspen) Cycloblastin (Pfizer) Maxidex (Alcon) AFT (AFT) AFT (AFT) Mycobutin (Pfizer) Salapin (AFT)

$4.99 $9.60 $25.71 $4.50 $1.68 $1.78 $213.19 $1.99

1% 1% 1% 1% 1% 1% 1% 1%

9. Tenders awarded to listed pharmaceuticals where an alternative brand is already listed – listing of the hospital tender winning brand of the pharmaceutical will occur in Part II of Section H of the Pharmaceutical Schedule on 1 June 2010; DV Limits and DV pharmaceuticals will apply from 1 August 2010; delisting of the other brand in Section H will occur on 1 August 2010.

The decisions were as follows:

Chemical Name Cytarabine** Cytarabine** Cytarabine**

Presentation; Pack size and type Inj 500 mg; 1 injection, vial Inj 1 g; 1 injection, vial Inj 2 g; 1 injection, vial

Hospital Supply Brand (Supplier) Pfizer (Pfizer) Pfizer (Pfizer) Pfizer (Pfizer)

Pack Price $18.15 $37.00 $31.00

DV Limit 1% 1% 1%

DV Pharmaceuticals Brand Name (Supplier) Mayne (Hospira) Mayne (Hospira) Mayne (Hospira)

** Pfizer’s brand of cytarabine will also be listed in Section B of the Pharmaceutical Schedule for PCT. The subsidy of cytarabine inj 1 mg for ECP will reduce from $0.30 per 10 mg to $0.27 per 10 mg from 1 August 2010 in Section B of the Pharmaceutical Schedule.

10. Tenders awarded to pharmaceuticals where no brand is listed - listing of the hospital tender winning brand of the pharmaceutical will occur in Section H of the Pharmaceutical Schedule on 1 June 2010 and DV Limits and DV Pharmaceuticals will apply from 1 August 2010.

The decisions were as follows:

Chemical Name

Presentation; Pack size and type

Hospital Supply Brand (Supplier)

Pack Price

DV Limit

DV Pharmaceuticals Brand Name (Supplier)

A345531 - qA15909

Page 4 of 5

---

Chemical Name Cytarabine***

Presentation; Pack size and type Inj 100 mg; 5 injections, vial

Hospital Supply Brand (Supplier) Pfizer (Pfizer)

Pack Price $76.00

DV Limit 1%

DV Pharmaceuticals Brand Name (Supplier) Mayne (Hospira)

*** Pfizer’s cytarabine, inj 100 mg, is already listed on Section B of the Pharmaceutical Schedule - the subsidy and price for Pfizer’s cytarabine, inj 100 mg will reduce accordingly from 1 June 2010.

Products where no tender is to be awarded for Sole Subsidised Supply or Hospital Supply Status The PHARMAC Board (or Chief Executive under delegated authority) resolved not to award tenders for Sole Subsidised Supply or Hospital Supply Status for some of the products listed in the Invitation to Tender, dated 4 December 2009.

The decisions were as follows:

Chemical Name Ascorbic Acid Ascorbic Acid Ascorbic Acid Beclomethasone Dipropionate Beclomethasone Dipropionate Budesonide Budesonide Dantrolene Sodium Emtricitabine Oxycodone Hydrochloride Oxycodone Hydrochloride Oxycodone Hydrochloride Oxycodone Hydrochloride Oxycodone Hydrochloride Oxycodone Hydrochloride Oxycodone Hydrochloride Oxycodone Hydrochloride Oxycodone Hydrochloride Oxycodone Hydrochloride Paracetamol Paracetamol Venlafaxine Venlafaxine Venlafaxine Venlafaxine Venlafaxine Venlafaxine

Line Item Inj 500 mg per 5 ml Eye drops 10% Tab 50 mg Metered aqueous nasal spray, 50 mcg per dose Metered aqueous nasal spray, 100 mcg per dose Metered aqueous nasal spray, 50 mcg per dose Metered aqueous nasal spray, 100 mcg per dose Inj 1 mg per ml, 20 ml Cap 200 mg Cap 5 mg Cap 10 mg Cap 20 mg Inj 10 mg per ml, 1 ml Inj 10 mg per ml, 2 ml Oral liq 5 mg per 5 ml Tab controlled-release 5 mg Tab controlled-release 20 mg Tab controlled-release 40 mg Tab controlled-release 80 mg Suppos 125 mg Suppos 250 mg Tab immediate-release 12.5 mg Tab immediate-release 25 mg Tab immediate-release 37.5 mg Tab immediate-release 50 mg Tab immediate-release 75 mg Tab immediate-release 100 mg

For the remaining products on the Invitation to Tender dated 21 December 2007, the Invitation to Tender dated 23 December 2008 and the Invitation to Tender dated 4 December 2009 where no announcement has been made, either a decision is still pending, or is provisional and subject to the product gaining market approval and having sufficient stock. We will keep you informed regarding any changes for the remaining tender products as further decisions are made. If you have any queries regarding this notification please contact PHARMAC on 0800 66 00 50.

A345531 - qA15909

Page 5 of 5